November 13, 2019

| | |
|---|---|
| To<br>Listing Department,<br>NATIONAL STOCK EXCHANGE OF INDIA LIMITED<br>Exchange Plaza,<br>Bandra Kurla Complex, Bandra (E),<br>MUMBAI -400 051<br><br>Company Code No. AUROPHARMA | To<br>The Corporate Relations Department<br>BSE LIMITED<br>Phiroz Jeejeebhoy Towers,<br>25th floor, Dalal Street,<br>MUMBAI -400 001<br><br>Company Code No. 524804 |

Dear Sir,

Sub: Completion of US FDA Inspection at our Unit IV – Reg.,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration (US FDA) inspected Company's Unit IV, a general injectable formulation manufacturing facility situated at Pashamylaram, Hyderabad, from 4th to 13th November 2019. At the end of the inspection, we have been issued a 'Form 483' with 14 observations. We believe that none of these observations are related to data integrity issues. The Company will respond to the US FDA within the stipulated timeline.

Please take the above information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LTD. * HYD. *